JPMA members of various pharmaceutical allele development of new cancer drugs (103) Until 2014.8.8

The court will -Wayne Wei's observation to Biotech and Healthcare Biotechnology, Sales & Marketing, Industry Analysis, Product Management, Healthcare, Lead & Management, Bio-medical Regulatory Analysis, Patent & Business Valuation log Japanese food menu latest new policies - new functions representation system allele recommended books:? create Medicines scientific Getting Medicines wa-do の yo u ni zu ku ra me cry ru Unmet Medical Needs in Common and Rare Diseases 2009 年 Q4 ~ 2010 in Q3 major new licensing case aggregated list of Japanese pharmaceutical industry situation recorded strengthen generics undertakings Novartis latest allele comments on a silver plate numerology Hospital Research Network capitalization challenges - above Sheng Hong medicine cabinet company for example silver plate numerology allele Information Systems Research Network on import and Outlook archive page health clinic center in September 2014 August 2014 July 2014 June 2014 May 2014 September 2013 classified ad hoc biopharmaceutical products industry analysis of medical care medicine health food regulations leading intellectual property management Uncategorized evaluate business marketing functions Register Login Log RSS Comments RSS WordPress.com
JPMA members of various pharmaceutical allele development of new cancer drugs (103) Until 2014.8.8 test drug name and dosage form of the active ingredient listed on the license expected performance or results, indications or symptoms of Japanese overseas development stage development stage company allele name Caprelsa other matters (vandetanib) has not been licensed medullary thyroid carcinoma (VEGFR, EGFR, RET tyrosine kinase inhibitor) Phase III has been listed allele AstraZeneca Caprelsa (vandetanib) has not been licensed papillary allele thyroid carcinoma and poorly differentiated adenocarcinoma (VEGFR, EGFR, RET tyrosine threonine kinase inhibitor) Phase III own R & D AstraZeneca Olaparib (AZD2281) has not been licensed BRCA mutations in ovarian cancer (PARP inhibitor) Phase III Phase III own R & D AstraZeneca Olaparib (AZD2281) allele BRCA gene mutation has not been licensed with recurrent ovarian Cancer (PARP inhibitor) Phase III Phase III AstraZeneca AZD4547 not yet licensed essence cancer (fibroblast growth factor receptor kinase inhibitor) Phase II has not yet developed its own AstraZeneca AZD5363 license essence cancer (AKT inhibitor) first / second of the first / second self-developed AstraZeneca MEDI-7183 has not been licensed ulcerative colorectal cancer (anti integrinα4β7) Phase II AstraZeneca AZD1208 not yet licensed essence cancer / malignant lymphoma allele (PIM kinase inhibitor) first / second first / II AstraZeneca AZD9150 not yet licensed lymphoma (STAT3 Antisense Drug) first / second phase of the first / second AstraZeneca AZD9291 allele has not been licensed non-small cell lung cancer (EGFR mutation) first / second phase of the first / second allele two AstraZeneca allele MEDI4736 not yet licensed essence cancer first / second phase of the first / second AstraZeneca MEDI-551 is not yet licensed hematopoietic malignancies (anti-CD19 antibody) first / second phase of the first / second own R & D AstraZeneca MEDI-573 has not been licensed essence cancer (anti-insulin-like growth factor (IGF) antibody) first / second phase of the first / second phase of joint development of AstraZeneca selumetinib (AZD6244) the substance has not been licensed cancer (MEK inhibitor) first / second two second / third phase has not yet developed its own AstraZeneca Alemtuzumab chronic lymphocytic leukemia license application has been listed Sanofi AVE0005 (Aflibercept) has not been licensed for colorectal cancer Phase III has not yet listed on imported goods Sanofi SAR245408 license essence cancer (breast cancer) first / Phase II Phase II (the first phase ) import goods Sanofi SAR125844 not yet licensed essence cancer first / second phase (first phase ) developed by Sanofi allele E7389 (Eribulin) / injection has been listed on the effectiveness of [additional] non-small cell lung cancer allele / microtubule dynamics inhibitor Phase III Phase III has been made inoperable or recurrent breast cancer efficacy license allele Eisai E7389 (Eribulin) / injection has been listed on the effectiveness allele of [additional] sarcoma / microtubule dynamics allele inhibitor, Phase three have made inoperable or recurrent breast cancer efficacy license Eisai E7080 (Lenvatinib) allele / oral thyroid cancer has not been licensed / VEGF receptor tyrosine kinase inhibitor multiple kinase inhibitor) Phase III Phase III Self club Eisai E7080 (Lenvatinib) / oral non-small cell lung cancer has not been licensed / VEGF receptor tyrosine kinase inhibitor multiple kinase inhibitor) Phase II from the community Eisai MORAb-003 (Farletuzumab) / injection has not been licensed platinum-sensitive ovarian Cancer / Phase III Phase III monoclonal antibody from the community Eisai E7040 / liver embolization additional medical material has been listed [effect] on the rich bloody cancer therapy vascular plug bolt third import (Biocompatibles Company) allele Eisai OPB-31121 has not been licensed anti- cancer drug first / second phase of the first / second self-developed system of Medicines Otsuka Corporation OPB-51602 has not been licensed cancer drugs first / second phase of the first / second self-developed system of Medicines Otsuka Corporation OPB-51602 yet License anticancer drugs first / second allele phase of the first / second self-developed system of Medicines Otsuka Corporation allele OCV-501 cancer vaccine not yet licensed the first / second phase of self-developed system of Medicines Otsuka Corporation OCV-501 has not been licensed cancer vaccine first / II developed its own system of Medicines Otsuka Corporation OCV-C02 has not been licensed cancer vaccine first / second self-developed system of Medicines Otsuka Corporation OCV-C02 has not been licensed allele cancer vaccine first / second self-developed system of Medicines Otsuka Corporation allele SGI- 110 Phase II ovarian cancer has not permit self-developed system allele of Medicines Otsuka Corporation SGI-110 Phase II hepatocellular carcinoma has not yet developed its own license Otsuka system Medicines Co. SGI-110 has not been licensed acute leukemia allele bone marrow second phase of self-developed system of Medicines Co. Otsuka OPB -111,077 not yet licensed essence cancer first / second phase of self-developed system of Medicines Otsuka Corporation YS110 injections not yet licensed 悪 of the skin swollen first / second period from the University of Tokyo, Science and Technology Agency to import goods Kissei Pharmaceutical NIK-333 (Peretinoin) : Oral yet permit suppression of recurrent hepatitis Phase III Phase III own R & D Kowa Company K-912 (NC-6300): injection of the substance has not been licensed cancer first / second and Nanocarrier jointly develop Kowa Company S-288310 injection has not yet permit bladder cancer, cancer peptide vaccine since Oncotherapy Sciense import Shionogi system Medicines Corporation S-488410 injection allele has not been licensed esophageal cancer peptide vaccine first / second period from Oncotherapy Sciense import Shionogi system Medicines Corporation S-222611 oral yet permit cancer HER2 / EGFR dual inhibitor since 膵 Viscera cancer Phase II system Medicines Agency Shionogi allele Co. Z-100 injection has been listed cervical cancer Phase III (a) own R & D (2) self-developed Zeria Pharmaceutical Z-360 锭 Ji yet permit a / II (a) own research and development (2) self-developed Zeria Pharmaceutical allele S-1 (Tegafur Gimeracil Oteracil potassium) oral gastric listed third Dapeng Yakuhin Kogyo Co., Ltd. S-1 (Tegafur Gimeracil Oteracil potassium ) Oral Phase III cervical cancer has been listed third Roc Yakuhin Kogyo Co., Ltd. S-1 (Tegafur Gimeracil Oteracil potassium) oral carcinoma has been listed third Dapeng Yakuhin Kogyo Co., Ltd. S-1 (Tegafur Gimeracil Oteracil potassium) in renal cell carcinoma oral listed second Dapeng Yakuhin Kogyo ABI-007 (Albumin binding Paclitaxel) injection of pancreatic cancer have been listed first / second period from Celgene Corporation to import Dapeng Yakuhin Kogyo TSU-68 (Orantinib) oral yet licensed Dapeng allele Yakuhin Kogyo TAS-102 oral carcinoma Phase III Phase III Phase III colorectal cancer has not been licensed third Roc Yakuhin Kogyo TAS-102 has not been licensed oral small-cell lung cancer second Phase II of the Roc Yakuhin allele Kogyo TAS-118 has not been licensed oral pancreatic cancer Dapeng Yakuhin Kogyo ET-743 (Trabectedin) injection has not been licensed malignant soft tissue tumors has been listed in the second part of the third phase of the European Phase III; self PharmaMar import Dapeng Yakuhin Kogyo TAS-114 (undecided) the substance has not been licensed allele cancer first / second phase of the first / second Dapeng Yakuhin Kogyo TAS-115 (undecided) the substance has not been licensed cancer first / second Dapeng Yakuhin Kogyo GA101 (Obinutuzumab) injection has not been licensed low-E of the degree of non-Hodgkin's lymphoma, high E of non-Hodgkin's lymphoma of the third phase of the third phase of import (foreign system of Medicines), to jointly develop domestic (foreign System Drugs) Medicines Co., Japan's new NS-187 (Bafetinib) has not been licensed oral B-cell chronic lymphocytic leukemia, the second phase of self-development, export to (U.S. CytRx) Japan's new Medicines Corporation RG435 (Bevacizumab) injection has been listed Indications expand] ovarian cancer admitted to import allele (Roche) and foreign manufacturing Medicines Corporation RG435 (Bevacizumab) injection has been listed Indications allele expand] breast cancer allele (secondary) III Import (Roche) and foreign manufacturing Medicines allele Co. RG3502 (Trastuzumab allele emtansine) injection has been listed breast cancer admitted to import ( Roche) and foreign manufacturing Medicines Co. RG3502 (Trastuzumab emtansine) injection has been listed Indications expand] breast cancer (secondary) III Import (Roche) and foreign manufacturing Medicines Co. RG3502 (Trastuzumab emtansine) injection allele has been listed Indications gastric third expansion] Introducing (Roche) and foreign manufacturing Medicines Corporation AF802 (Alectinib hydrochloride) oral yet permit non-small cell lung cancer application first / second period allele from society and foreign manufactured Medicines Co. RG7204 allele (Vemurafenib) oral yet licensed allele E of Black color swollen application to import (Roche) and foreign manufacturing Drugs Corporation RG1273 (Pertuzumab) injection has been listed Indications expand] breast cancer (secondary) III Import (Roche) and foreign manufacturing Medicines Co. RG1273 (Pertuzumab) allele injection has been listed Indications expand] Phase III gastric import (Roche) allele and foreign System Drugs Corporation GA101 / RG7159 injection has not been licensed low-grade non-Hodgkin's lymphoma Phase III Import (Roche) jointly developed with Japan's new foreign manufacturing Medicines Medicines Co. GA101 / RG7159 injection has not been licensed in high grade non-Hodgkin's lymphatic Stage III tumors import (Roche) allele and foreign injection system Medicines Co. RG7446 non-small cell lung cancer has not been licensed to import III (Roche) and foreign manufacturing Medicines Co. GC33 / RG7686 Phase II liver cancer allele injection has not been licensed since foreign manufactured Medicines Agency Corporation RG340 (Capecitabine) Oral listed Indications expand] gastric (auxiliary) second import (Roche), jointly developed with Yakult foreign system Medicines Co. CKI27 / RG7304 substance allele of oral cancer has not yet licensed the first / second phase of the first / second period from foreign clubs System Drugs Ltd. RG7321 oral cancer has not been licensed in real terms the first / second import (Roche) and foreign manufacturing Medicines Corporation Methadone hydrochloride oral listed